Methods and compositions for immunomodulation
US6210669A · kind A · utility
71Cited by
1References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 3, 1997 |
| Grant date | Apr 3, 2001 |
| Priority date | — |
| Expiry date | Oct 3, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The instant invention discloses the unexpected result that two anti-4-1BB monoclonal antibodies can inhibit both primary and secondary humoral responses to at least T-cell dependent antigens in vivo. Such antibodies provide a novel approach to immunosuppression and cancer therapy in vivo.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.